4B6L
Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design
Summary for 4B6L
Entry DOI | 10.2210/pdb4b6l/pdb |
Descriptor | SERINE/THREONINE-PROTEIN KINASE PLK3, 4-[[(4R)-5-cyclopentyl-4-ethyl-3a,4-dihydro-3H-[1,2,4]triazolo[4,3-f]pteridin-7-yl]amino]-N-cyclopropyl-3-methoxy-benzamide, SULFATE ION, ... (4 entities in total) |
Functional Keywords | transferase, kinase inhibitors, water-mediated h-bond |
Biological source | HOMO SAPIENS (HUMAN) |
Cellular location | Cytoplasm: Q9H4B4 |
Total number of polymer chains | 1 |
Total formula weight | 32790.87 |
Authors | Brown, K.,Charrier, J.D.,Durrant, S.,Griffiths, M.,Hudson, C.,Kay, D.,Knegtel, R.,ODonnell, M.,Pierard, F.,Twin, H.,Weber, P.,Young, S. (deposition date: 2012-08-14, release date: 2013-08-21, Last modification date: 2024-05-08) |
Primary citation | Brown, K.,Charrier, J.D.,Durrant, S.,Griffiths, M.,Hudson, C.,Kay, D.,Knegtel, R.,Odonnell, M.,Pierard, F.,Twin, H.,Weber, P.,Young, S. Discovery of Oral Polo-Like Kinase (Plk) Inhibitors with Enhanced Selectivity Profile Using Residue Targeted Drug Design To be Published, |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report